Agilent, GKSA-302, AdvanceBio 2-AA G0F / FA2 N-glycan Standard

AdvanceBio 2-AA G0F / FA2 N-glycan Standard. N-glycan (asialo, agalacto biantennary core-substituted with fucose) labeled with 2-aminobenzoic acid (2-AA, also known as anthranilic acid), for use as a qualitative standard in applications such as liquid chromatography (LC). Alternative glycan names: F(6)A2, NGA2F

Specifications:
Chemical Structure:
Label: 2-AA
Monoisotopic Mass: MWGlycan + 121.05276 = 1583.5972
Name: G0F
Oxford Name: F(6)A2
Standard Type: Complex-type Native N-Glycan
Unit: 100 pmol

**********The following product description is generated by AI and is for reference only. If you have any questions, please contact customer service.**********
The AdvanceBio 2-AA G0F / FA2 N-glycan Standard is a high-quality, ready-to-use glycan reference material optimized for robust and reproducible glycan analysis in biopharmaceutical research and quality control. Featuring 2-aminobenzoic acid (2-AA) labeling, this standard provides precise retention times and peak identification, facilitating accurate system suitability testing and glycan profiling workflows.

Well suited for confirming instrument performance and supporting method development, this product is invaluable for laboratories conducting structural characterization, quantitation, and comparability studies of monoclonal antibodies and other glycoproteins. The purified G0F / FA2 structure enables calibration and alignment across analytical methods including HPLC, UHPLC, and LC-MS.

Designed for seamless integration with Agilent AdvanceBio Glycan Mapping columns, AdvanceBio LC systems, and compatible with a range of popular glycan analysis platforms, this standard ensures confidence in data quality and regulatory compliance. Its stable and reproducible formulation makes it ideal for routine use in bioprocess development and release testing. Researchers can rely on this standard for precise method validation, troubleshooting, and system monitoring, as well as for supporting comparability and biosimilarity studies in therapeutic protein development.